On March 8, 2022 Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, reported the upcoming presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 of pre-clinical data for ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory Acute Myeloid Leukemia (AML) (Press release, Arcellx, MAR 8, 2022, View Source [SID1234609721]). ACLX-002 can be activated in a dose dependent manner in vivo with soluble protein adapters allowing for controllability and adaptability to address intra-and inter-patient disease heterogeneity and off-target antigen expression that are often associated with serious dose-limiting adverse events in AML.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the Presentation are as Follows:
Session Category: Immunology
Session Title: Adoptive Cell Therapy 2
Session Date and Time: Sunday, April 10, 2022, 1:30 PM – 5:00 PM
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Poster Board Number: 22
Permanent Abstract Number: 587